| Document |
Document Title |
|
WO/2001/024786A1 |
Compounds of general formula (I), useful as preventive or therapeutic drugs for diabetes, wherein A is optionally substituted aryl or optionally substituted heteroaryl; B is lower alkyl, optionally substituted aryl, or the like; X?1¿ is...
|
|
WO/2001/025189A1 |
The invention relates to compounds of formula (I), wherein R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30) and R(31) have the meanings cited in the Claims and are especially suitable as novel antiarrhythmic active agents, in partic...
|
|
WO/2001/021577A2 |
A melanin-concentrating hormone antagonist which comprises a compound of formula (I) wherein Ar?1¿ is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main c...
|
|
WO/2001/019778A1 |
The invention relates to the use of compounds of formula (I) and of their salts and stereoisomers in the production of medicaments for treating cardiovascular diseases.
|
|
WO/2001/019780A2 |
The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof used in the production of medicaments for the treatment of cardiovascular diseases.
|
|
WO/2001/017982A1 |
The present invention includes benzophenone compounds (I) which are useful in the treatment of HIV infections.
|
|
WO/2001/017953A1 |
The invention relates to non-peptidic compounds that possess bioactive properties, such as the ability to protect neuronal cells from otherwise lethal treatments or the ability to promote the growth or regeneration of neuronal cells. In ...
|
|
WO/2001/014328A2 |
Compounds of Formula (I) are antagonists of VLA-4 and/or $g(a)4$g(b)7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical ...
|
|
WO/2001/010825A1 |
Novel bactericides having an excellent controlling effect on plant disease injury (in particular, wheat powdery mildew and cucumber gray mold) without exerting any undesirable effect on crops. Carbamate derivatives represented by general...
|
|
WO/2001/009096A2 |
Compounds of formula (I), are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
|
|
WO/2001/009088A1 |
Urea and thiourea derivatives inhibit cell function of the chemokine receptor CCR-3. These compounds offer an effective means for treating a range of diseases thought to be mediated by the CCR-3 receptor. A variety of useful urea and thi...
|
|
WO/2001/008633A2 |
A novel process for the production of an improved form of Form I celiprolol hydrochloride, N'-[3-Acetyl-4-[(1,1-dimethylethyl)amino]-2-hydroxy-propoxy]
phenyl]-N,N-diethyl urea hydrochloride, is described.
|
|
WO/2001/007400A1 |
Substances inhibiting cell adhesion mediated by adhesion molecules (in particular, VLA-4) which enable the prevention and treatment of inflammatory diseases caused by leukocyte (for example, monocyte, lymphocyte or eosinocyte) infiltrati...
|
|
WO/2001/007020A2 |
The invention relates to the use of carboxylic acid amides of general formula (I) for inhibiting telomerase, wherein A, B and R¿1? to R¿5? are defined as per claim (1). The invention also relates to novel carboxylic acid amides of gene...
|
|
WO/2001/005751A1 |
The present invention relates to compounds of formula (I) wherein R¿1? and R¿2? independently represent one or more, same or different substituents selected from the group consisting of halogen, hydroxy, mercapto, trifluoromethyl, amin...
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
WO/2001/000206A1 |
Compounds that selectively inhibit the binding of ligands to $g(a)4$g(b)1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by formula (I). As selective inhibi...
|
|
WO/2001/000581A1 |
The present invention includes array of new chiral ligands that are optically active or racemic. These ligands are bidentate, tridentate, tetradentate or pentadentate ligands which include P-P, P-N, N-N, mixed P-N, Schiff base or carbene...
|
|
WO/2000/075106A2 |
Peptoid compounds of Formula (I) and Formula (II) are disclosed. The compounds are useful in the treatment of matrix metalloproteinase-mediated disorders. The invention is further directed to combinatorial libraries of these compounds an...
|
|
WO/2000/073262A1 |
The invention relates to novel polymerizable, olefinically unsaturated monomers with alkaline groups of general formula (I), wherein R?1¿ is H or methyl, L¿1?, L¿2? independently represent alkylene with 1 to 6 carbon atoms, A is oxyge...
|
|
WO/2000/069810A1 |
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or preventio...
|
|
WO2000035998B1 |
The invention relates to a method of increasing the viscosity of supercritical CO2 by combining a compound having a CO2-philic functional group and an aggregating functional group which enables the compound to form a supramolecular netwo...
|
|
WO/2000/066544A1 |
The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents of formula (I) wherein n is 0 or 1, and where n is 1 each C¿6?R¿5? moiety may be the same or different; X denotes a bond or a group providin...
|
|
WO/2000/066545A1 |
The invention concerns compounds of general formula (I) wherein: R¿1? represents either a hydrogen atom, or an amino group, or a C¿1?-C¿4? alkyl group, or a C¿1?-C¿6? alkoxycarbonyl group, or a -OH group; R¿2? represents either a C...
|
|
WO/2000/066618A1 |
The invention relates to new compounds which bind to integrin receptors, as well as to their production, their use as integrin receptor antagonists and for the treatment of diseases, pharmaceutical preparations containing said compounds ...
|
|
WO/2000/064866A1 |
A compound of formula (I) wherein A' is NH or NR?6¿, where R?6¿ is C¿1-6?alkyl, C¿2-6?alkenyl, C¿2-6?alkanoyl or C¿1-6?alkoxycarbonyl; B is oxygen or sulphur; Y' is a specified linker group; m is from 0 to 5; n is from 0 to 4; R?1Â...
|
|
WO/2000/063159A1 |
A description is given here of novel solid and stable derivatives of (-)-verbenone having formula (I) wherein, when X = O Z = H, =CHAr, =C(OH)COOEt, =NOR; Y = H, NH¿2?, NH¿3??+¿ X¿1??-¿, NHCOAr, NHCOR, NHCONHR, NHCONHAr; X¿1??-¿ =...
|
|
WO/2000/061546A2 |
Described herein are novel 1-aryl-3-(2-chloroethyl)ureas derivatives. These derivatives are useful anticancer agents having excellent specify towards cell targets and potent antineoplastic activity without systemic toxicity or mutagenici...
|
|
WO/2000/061548A1 |
The N-substituted-N'-substituted urea derivative of formula (a), analogues of the same, or medicinally acceptable salts of both, having a TNF-production inhibiting effect.
|
|
WO/2000/061545A1 |
Compounds of the formula (I) are useful in the treatment of various disorders including, but not limited to, cancer (tumor metathesis, tumorgenesis/tumor growth), angiogenesis (as in cancer, diabetic retinopathy, rheumatoid arthritis), r...
|
|
WO/2000/059875A2 |
Derivatives of aryl and heterocyclic ureido and aryl and heterocyclic carboxamido phenoxy isobutyric acids have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproduc...
|
|
WO/2000/058293A2 |
The present invention relates to compounds of formula (I) wherein R?1¿, R?2¿, R?3¿ and R?4¿ are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secr...
|
|
WO/2000/058295A2 |
The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition p...
|
|
WO/2000/056331A1 |
The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well ...
|
|
WO/2000/055126A2 |
The present invention relates to novel $i(N)-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and $i(N)-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2000/055125A2 |
The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2000/055124A2 |
The present invention relates to novel cysteine protease inhibitors; the pharmaceutically acceptable salts and $i(N)-oxides thereof; their uses as therapeutic agents and the methods of their making.
|
|
WO/2000/054759A2 |
The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The c...
|
|
WO/2000/053583A1 |
The present invention comprises small molecular weight, non-peptidic inhibitors of formula (I) of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
|
|
WO/2000/053576A1 |
Novel N?$g(a)¿-alkyl- or alkenylcarbamoyl-N?$g(v)¿-acylamino acid esters represented by general formula (1); (wherein R?1¿ is linear or branched C¿7?-C¿21? alkyl or alkenyl; R?2¿ is linear, branched or cyclic C¿1?-C¿22? alkyl or ...
|
|
WO/2000/052089A1 |
Disclosed are compositions comprising nucleators for crystallizable thermoplastic polymers and, in particular, chemical compounds used as nucleators that comprise moieties that are capable of forming intermolecular hydrogen bonds and tha...
|
|
WO/2000/051970A1 |
Amide compounds of formula (I) wherein R?1¿ and R?2¿ are each aryl or ar(lower)alkyl, or are taken together to form lower alkylene or lower alkenylene, each of which may be substituted with aryl or may be condensed with a cyclic hydroc...
|
|
WO/2000/051972A1 |
The invention provides compounds of formula (I), wherein R?1¿ and R?2¿ independently represent H or C¿1-6? alkyl; R?3¿ represents phenyl substituted by at least one group selected form halo, CF¿3?, OCF¿3?, CN, OH, C¿1-6? alkyl and...
|
|
WO/2000/049002A1 |
An improved process and intermediate compounds (N) for the preparation of 2-(N,N-disubstituted)amino-4-(perfluoroalkyl)-1,3-oxazin-6-o
ne compounds having structural formula (I) and an improved process for the preparation of 6-(perfluoro...
|
|
WO/2000/048593A1 |
Biologically stable inhibitors of soluble epoxide hydrolases are provided. The inhibitors can be used, for example, to selectively inhibit epoxide hydrolase in therapeutic applications such as treating inflammation, for use in affinity s...
|
|
WO/2000/047539A1 |
A composition comprising hydrogen fluoride and a compound which is liquid in the normal state (25°C, 1 atm), has a boiling point of 120°C or higher, and has a pKa at 25°C of 12 or higher; and use of the composition as a fluorinating a...
|
|
WO/2000/046187A2 |
The present invention is directed to agmatine and polyamine analogs and their use as drugs, as well as agricultural or environmentally useful agents. As drugs, the analogs decrease cellular polyamine levels, possibly by inducing antizyme...
|
|
WO/2000/046182A1 |
The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide (hereinafter referred to as a 'protected/activated salicylamide'). The method comprises the steps of (a) alkylat...
|
|
WO1999064033A9 |
This invention relates to novel multibinding compounds that bind to the enzyme phosphodiesterase V (PDE V) and modulate its activity. The compounds of this invention comprise 2-10 PDE V modulator (particularly inhibitor) ligands covalent...
|
|
WO/2000/043354A2 |
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mamma...
|
